AVAnna Vicco

Anna Vicco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anna Vicco has a total of 130 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sero-catalytic and spatial modeling of dengue virus force of infection in Timor-Leste

    by Paul Arkell, Filipe de Neri Machado, Anna Vicco, Victoria M. Cox, Maria Y. Tanesi, Deolindo Ximenes, Wes Hinsley, Frederico Bosco, Nelia Gomes, Tessa Oakley, et al.

    Dengue virus (DENV) infection causes significant morbidity and mortality across tropical and sub-tropical regions, including in Timor-Leste. In this study we present the results of a national, population-representative serological survey, used to determine the drivers of observed variations in DENV force-of-infection (FOI, i.e. the average annual per-capita risk of infection for a susceptible person) at high spatial resolution. Households were randomly selected from census data and occupants aged above one year were tested using the Panbio Indirect dengue IgG enzyme-linked immunosorbent assay between October 2021 and February 2023. Sero-catalytic models accounting for household effect were applied to estimate the DENV FOI in enumeration areas (EAs, roughly equivalent to neighbourhoods/villages). Spatial models were applied to the local FOI estimates to assess their associations with climate and environmental factors, and to predict the FOI across the rest of Timor-Leste. A total of 4780 individuals from 1755 households across 102 EAs participated. DENV seroprevalence and FOI estimates were highly spatially heterogeneous across Timor-Leste, ranging from 0.010 (95% Credible Interval (CrI): 0.005, 0.018) in EA 10104032 in Fatubossa, municipality Aileu, to 0.519 (0.295, 0.816) in EA 40403012 in Goulolo, municipality Bobonaro. Relative humidity was negatively associated with DENV FOI. The spatial models predicted highest DENV FOI along the Northern and Eastern coasts, with hotspots of transmission in Dili and Baucau cities. Findings will strengthen surveillance and guide the implementation of additional DENV control strategies such as Wolbachia -carrying mosquitoes (currently being deployed in some parts of Timor-Leste), or vaccination.

  • Open Access

    Overall and serotype-specific dengue virus transmission intensity in Mexico, 2016–2023: A modelling study of case-notification data

    by Oliver S. Simmons, Anna Vicco, Ruth A. Martínez-Vega, José Ramos-Castañeda, Ilaria Dorigatti

    Background: Mexico, and the Americas region more widely, have experienced increased dengue incidence in recent years, and there are concerns that the changing climate may enhance dengue virus (DENV) transmission in the future. Whilst previous studies have characterised spatial heterogeneities in the long-term average risk of DENV infection in Mexico, the extent to which DENV transmission changes year-to-year has not been investigated. Furthermore, the extent to which DENV’s four serotypes (DENV-1, DENV-2, DENV-3 and DENV-4) may differ in their transmissibility remains poorly characterised, both in Mexico and globally. Methods and findings: In this study, we characterised the spatial and temporal variations in DENV transmission intensity, as defined by the force of infection, across 27 states in Mexico. We analysed annual dengue case data reported to the National Epidemiological Surveillance System (SINAVE) in Mexico between 2016 and 2023, which comprised 833,629 probable or confirmed cases, using established catalytic models and a new, serotype-specific extension of these models that characterises differences in the transmission intensity of the different serotypes. We found evidence of large spatial, temporal, and serotype-specific heterogeneities in transmission intensity across Mexico. Serotype-specific force of infection estimates suggest that DENV-1 and DENV-2 have historically circulated at high levels across Mexico, with DENV-4 showing a low transmission intensity throughout the study period. We found evidence of increasing DENV-3 transmission intensity across some states in recent years, coinciding with large outbreaks. The extent to which the serotype-specific transmission intensity estimates generated in this study are affected by potential heterogeneities in case reporting across states and through time remains to be validated in future studies. Conclusions: This work quantifies serotype-specific differences in DENV transmission intensity using routinely collected case-notification data and demonstrates how extensive RT-PCR testing and new rapid diagnostic tests capable of discerning infecting serotypes can help to better understand the contributions of different serotypes to DENV transmission. The methods developed in this study contribute to the development of a better understanding of the past and current burden of dengue infection, which can help to refine assessments of the potential impact of existing and new interventions in future analyses.

  • Open Access

    An Economic Evaluation of Dengue Vaccination with Qdenga in Thailand: Findings from a Dynamic Transmission Model

    by Jarawee Sukmanee, Neil M. Ferguson, Phornnaphat Chertchinnapa, Clare McCormack, Anna Vicco, Bethan Cracknell Daniels, Sunate Chuenkitmongkol, Nakorn Premsri, Yot Teerawattananon, Ilaria Dorigatti, et al.

    Background: Dengue is highly endemic in many tropical and subtropical regions, including Thailand. As no specific treatment is available, vaccination is an important preventive strategy. The Qdenga (TAK-003) live-attenuated quadrivalent dengue vaccine is recommended by the World Health Organization for routine immunisation programmes in high-transmission settings with substantial disease burden. However, an independent country-specific economic evaluation is needed before inclusion in Thailand's National Immunization Program. This study evaluated the cost-effectiveness and budget impact of Qdenga vaccination strategies in Thailand.Methods: Cost-utility and budget impact analyses were conducted using a previously developed dengue transmission model. Qdenga vaccination scenarios, varying by vaccination age, vaccine mode of action (protection against disease only or against both disease and infection), and duration of waning (5 or 10 years), were compared with a no vaccination comparator. Costs and health outcomes, measured in quality-adjusted life years (QALYs), were projected over a 30-year time horizon.Findings: A national vaccination programme cumulatively targeting 15 million children aged 6 years could prevent 1·7 million symptomatic dengue cases and 382,000 hospitalisations. In the base-case analysis, routine vaccination targeting 6-year-olds would generate incremental costs of US$1,186 million and gain of 41,169 QALYs, resulting in an ICER of US$30,458/QALY. This exceeds Thailand's cost-effectiveness threshold (US$4,739/QALY) and yields an incremental net monetary benefit of –US$996 million. The annual government budget impact over the first five years was estimated to vary between US$66·4–70·9 million.Interpretation: Qdenga vaccination could substantially reduce symptomatic dengue cases and hospitalisations in Thailand. However, at its current price, the programme is unlikely to be cost-effective and would have a considerable budget impact. Price negotiation is therefore recommended before inclusion in the national immunisation programme.

  • Open Access

    Combining vaccination with w Mel for dengue control in Brazil

    by Emilie Finch, Angkana T. Huang, Clare McCormack, Anna Vicco, Julio Croda, Neil M. Ferguson, Ilaria Dorigatti, Henrik Salje

    Dengue virus is a severe threat to global health. Novel vaccine and Wolbachia technologies offer a potential path to dengue control; however, it remains unclear how to use these approaches in tandem. Using metapopulation transmission models, we simulated future dengue burden in Brazil. We estimated that w Mel releases in 300 municipalities could avert 12-22% of cases over the next 10 years, while a national vaccination campaign could avert 8-10% of cases in the total population and 39-45% within the vaccinated cohort. Projecting forward 40 years, we found w Mel releases would drive up the mean age of cases beyond increases due to the ageing population and increase population susceptibility to dengue. Finally, w Mel releases can help mitigate the future burden in southern Brazil where climate change is rapidly increasing dengue virus risk. These findings highlight the need to consider the two technologies in parallel to optimise efforts to combat future dengue burden.

  • Open Access

    A systematic review of Nipah virus disease epidemiological parameters, outbreaks and mathematical models

    by Tristan M Naidoo, Christian Morgenstern, Patrick Doohan, Rhys Earl, Thomas Rawson, Richard J Sheppard, Joseph T Hicks, Sreejith Radhakrishnan, Rob Johnson, Anna-Maria Hartner, et al.

    We conducted a systematic review (PROSPERO CRD42023393345) characterising the epidemiology, outbreaks and mathematical models of Nipah virus (NiV), an important public health threat in South and Southeast Asia. We extracted 243 parameters, 89 risk factors, 39 models and 23 distinct outbreaks from 119 papers. IgG seroprevalence estimates ranged from 0% to 12.5%. NiV causes severe disease, with pooled case-fatality ratio estimates ranging widely from 9.1% (95%CI: 0.2%-41.3%) in Singapore to 81.9% (95%CI: 71.9%-88.9%) in Bangladesh. NiV’s natural history is poorly characterised; we estimated a median incubation period of 8.77 days (95%CI: 7.53-10.02) based on 8 studies. Transmission parameter estimates were scarce, and all but one central estimate of the basic reproduction number were below 1. NiV mathematical models (n=39) were rarely fitted to data (n=8). All extracted information is accessible via our R package, epireview , a dynamic resource for informing responses to future outbreaks of NiV and related pathogens.


  • Open Access

    Dengue in Sri Lanka: Analysing Spatiotemporal Variations in Transmission Intensity through the Analysis of Case-Notification Data

    by Preshila Samaraweera, Anna Vicco, Sudath Samaraweera, Garyfallos Konstantinoudis, D. S. Anoja F. Dheerasinghe, Sakunthala Janaki, Niroshini Adikaram, Jagath Amarasekara, Chathura Edirisuriya, Anjalee De Silva, et al.

    Background: The recent licensure of the TAK-003 dengue vaccine, and advances in vector management provide new opportunities for dengue control. To evaluate their local impact, it is necessary to characterise dengue virus (DENV) transmission intensity. Age-stratified case-notification data from routine surveillance can help estimate transmission intensity over time and space, revealing hidden infection burden and transmission hotspots, even in areas with unequal surveillance or healthcare access. Methods: We applied time-constant and time-varying catalytic models to age-stratified dengue incidence data (2017-2024) across Sri Lankan districts, to characterise heterogeneities in the Force of Infection (FOI), the per-capita annual risk of infection for a susceptible person. We reconstructed the sensitivity of surveillance by estimating the proportion of infections reported and also explored associations between the FOI and climatic and socioeconomic factors using spatiotemporal regression models within the Integrated Nested Laplace Approximations (INLA) framework. Findings: FOI estimates and reporting rates were highly heterogeneous across the country, with the estimated seroprevalence at age 9 years ranging from 7.9% (95% Credible Interval CrI: 6.0, 10.0%) in Polonnaruwa to 46.4% (95%CrI: 37.1, 55.5%) in Jaffna. In the multivariable analysis no climatic or socioeconomic variable showed a statistically significant association with the dengue yearly average FOI, after adjustment for spatial and temporal random effects. Interpretation: These results suggest that the dengue FOI and the sensitivity of surveillance are highly heterogeneous across Sri Lanka and the introduction of the TAK-003 dengue vaccine needs to be carefully evaluated. Wellcome Trust Grant Number(s): 213494/Z/18/Z, 226072/Z/22/Z, 226727/Z/22/Z and 228185/Z/23/Z Data Availability Statement: The code and the Shinyapp to estimate the dengue FOI are available at https://github.com/mrc-ide/SriLanka_FOI/ together with a simulated dataset of the Sri Lanka number of cases by year, district and age-group. The reported case-notification data collected by the Ministry of Health of Sri Lanka can be accessed upon request. Requests should be addressed to the National Disease Control Unit which can be contacted at ndcu2010@yahoo.com

  • Open Access

    A systematic review and meta-analysis of Zika virus epidemiology

    by Kelly McCain, Anna Vicco, Christian Morgenstern, Thomas Rawson, Tristan M. Naidoo, Sangeeta Bhatia, Dominic P. Dee, Patrick Doohan, Keith Fraser, Anna-Maria Hartner, et al.

    Zika virus (ZIKV), classified as a priority pathogen by the World Health Organization, is an Aedes -borne arbovirus that can cause neurological complications and birth defects in newborns of mothers infected during pregnancy. We conducted a systematic review of peer-reviewed studies reporting ZIKV epidemiological parameters, transmission models and outbreaks (PROSPERO CRD42023393345) to characterize its transmissibility, seroprevalence, risk factors, disease sequelae and natural history. We performed meta-analyses of the proportions of congenital Zika syndrome, pregnancy loss among ZIKV-infected mothers and symptomatic cases. We extracted information from 574 studies. Across 418 included studies assigned a high-quality score, we extracted 969 parameters, 127 outbreak records and 154 models. Using random-effects models, we estimated proportions of congenital Zika syndrome (4.65%, 95% confidence interval (CI): 3.38–6.67%), pregnancy loss (2.48%, 95% CI: 1.62–3.78%) and symptomatic cases (51.20%, 95% CI: 38.00–64.23%). Seroprevalence estimates ( n = 354) were retrieved beyond South America and French Polynesia. Basic reproduction number estimates ( n = 77) ranged between 1.12 and 7.4. We found 66 human epidemiological delay estimates, including the intrinsic incubation period ( n = 11, range: 4–12.1 days), infectious period ( n = 15, range: 3–50 days), extrinsic incubation period ( n = 22, range: 5.1–24.2 days) and serial interval ( n = 27, range: 7.4–32.9 days). These data are available in the R package ‘epireview’ (version 1.4.5). We provide a comprehensive systematic summary of ZIKV epidemiology, revealing large heterogeneities and inconsistencies in the reporting of parameter estimates, study designs and parameter definitions and underscoring the need for standardized epidemiological definitions.


  • Open Access

    A systematic review of Zika virus disease: epidemiological parameters, mathematical models, and outbreaks

    by Kelly McCain, Anna Vicco, Christian Morgenstern, Thomas Rawson, Tristan M. Naidoo, Sangeeta Bhatia, Dominic P. Dee, Patrick Doohan, Keith Fraser, Anna-Maria Hartner, et al.

    Background: Zika virus (ZIKV) is an Aedes-borne arbovirus that can cause serious risks of neurological complications and birth defects in newborns of mothers infected during pregnancy. ZIKV is classified as a priority pathogen by the World Health Organization. Methods: We conducted a systematic review of peer-reviewed studies reporting ZIKV epidemiological parameters, transmission models, and outbreaks (PROSPERO #CRD42023393345) to characterise its transmissibility, seroprevalence, risk factors, disease sequelae, and natural history. We performed a meta-analysis of Congenital Zika Syndrome (CZS), pregnancy loss probabilities amongst ZIKV-infected mothers and the proportion of symptomatic cases. Findings: We extracted information from 574 of 27,491 identified studies. Across 418 included studies assigned a high-quality score, we extracted 969 parameters, 127 outbreak records, and 154 models. We estimated a pooled total random effect of CZS probability (4.65%), pregnancy loss probability (2.48%), and proportion of symptomatic cases (51.20%). Seroprevalence estimates (n=354) were retrieved beyond South America and French Polynesia. The basic reproduction number estimates (n=77) ranged between 1.12 and 7.4. We found 66 human epidemiological delay estimates, ranging 4-12.1 days for the intrinsic incubation period (n=11), 3-50 days for the infectious period (n=15), 5.1-24.2 days for the extrinsic incubation period (n=22), and 7.4-32.9 days for the serial interval (n=27). These data are available in the R package epireview . Interpretation: This study provides the most comprehensive systematic summary of the ZIKV epidemiological information currently available in the literature. Large heterogeneities and inconsistencies in the reporting of parameter estimates, study designs, and parameter definitions were found, underscoring the need for standardised epidemiological definitions in future publications. Funding: Academy of Medical Sciences, British Heart Foundation, Community Jameel, Diabetes UK, Imperial College London, National Institute for Health and Care Research, Royal Society, Schmidt Sciences, UK Department for Business, Energy, and Industrial Strategy, UK Medical Research Council, United Nations Foundation, Wellcome Trust. Research in Context: Evidence before this study: We searched Web of Science and PubMed from database inception to October 31, 2024 to collate epidemiological parameters, mathematical models, and outbreaks of Zika virus (ZIKV). We found 66 systematic reviews on ZIKV since 2016: of these, 29 focussed on Congenital Zika Syndrome (CZS) and/or Guillain-Barré Syndrome, 19 on ZIKV transmission, 16 on the distribution and burden of ZIKV infection and disease and the remaining on clinical presentation, severity, forecasting, time-to-event, risk mapping and vaccines and therapeutics. The published systematic reviews included between 4 to 204 publications, and most (75%) had a global scope. Only 5 systematic reviews conducted a meta-analysis assessing the overall probability of CZS upon infection in the mother, and only 1 review investigated the probability of CZS by trimester of pregnancy (using 2 articles). Added value of this study: In this systematic review, we extracted information from 574 relevant studies, which makes this the most comprehensive synthesis of Zika parameters for outbreak response to date. From 418 studies with a high-quality assessment score, we extracted 969 epidemiological parameters, 127 outbreak records and 154 transmission models, most of which were published after the 2016 outbreak. We extracted and analysed 354 geolocated and time-stamped seroprevalence estimates; 100 basic and 15 effective reproduction number estimates from 21 countries; 66 human epidemiological delays and 22 extrinsic incubation periods. Our meta-analysis provides robust pooled estimates of the proportion of symptomatic cases (51.20%) and CZS probability (4.65%), also stratified by trimester based on maternal ZIKV infection (based on 7 publications), addressing a gap present in most previous reviews. Implications of all the available evidence: This study provides the most comprehensive overview of ZIKV epidemiology to date, serving as a valuable resource for future modelling studies and stakeholders developing preparedness and response plans to control future outbreaks.

  • Open Access

    Severe acute respiratory syndrome (SARS) mathematical models and disease parameters: a systematic review and meta-analysis

    by Christian Morgenstern, Thomas Rawson, Isobel Routledge, Mara Kont, Natsuko Imai-Eaton, Janetta Skarp, Patrick Doohan, Kelly McCain, Rob Johnson, H. Juliette T. Unwin, et al.

    We conducted a systematic review (PROSPERO CRD42023393345) of severe acute respiratory syndrome (SARS) transmission models and parameters characterising its transmission, evolution, natural history, severity, risk factors and seroprevalence. Information was extracted using a custom database and quality assessment tool. We extracted 519 parameters, 243 risk factors, and 112 models from 288 papers. Our analyses show SARS is characterised by high lethality (case fatality ratio 10.9%), transmissibility (R 0 range 1.1-4.59), and is prone to superspreading (20% top infectors causing up to 91% of infections). Infection risk was highest among healthcare workers and close contacts of infected individuals. Severe disease and death were associated with age and existing comorbidities. SARS’s natural history is poorly characterised, except for the incubation period and mean onset-to-hospitalisation. Our associated R package, epireview, contains this database, which can continue to be updated to maintain a living review of SARS epidemiology and models, thus providing a key resource for informing response to future coronavirus outbreaks.


  • Open Access

    A scoping literature review of global dengue age-stratified seroprevalence data: estimating dengue force of infection in endemic countries

    by Anna Vicco, Clare McCormack, Belen Pedrique, Isabela Ribeiro, Gathsaurie Neelika Malavige, Ilaria Dorigatti